MA28822B1 - Benzamides substitues trifluoromethyle comme inhibiteurs de kinase - Google Patents

Benzamides substitues trifluoromethyle comme inhibiteurs de kinase

Info

Publication number
MA28822B1
MA28822B1 MA29711A MA29711A MA28822B1 MA 28822 B1 MA28822 B1 MA 28822B1 MA 29711 A MA29711 A MA 29711A MA 29711 A MA29711 A MA 29711A MA 28822 B1 MA28822 B1 MA 28822B1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
substituted trifluoromethyl
trifluoromethyl benzamides
benzamides
substituted
Prior art date
Application number
MA29711A
Other languages
English (en)
Inventor
Giorgio Caravatti
Pascal Furet
Patricia Imbach
Georg Martiny-Baron
Lawrence Blas Perez
Tao Sheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28822B1 publication Critical patent/MA28822B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
MA29711A 2004-08-11 2007-02-22 Benzamides substitues trifluoromethyle comme inhibiteurs de kinase MA28822B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417905.7A GB0417905D0 (en) 2004-08-11 2004-08-11 Organic compounds

Publications (1)

Publication Number Publication Date
MA28822B1 true MA28822B1 (fr) 2007-08-01

Family

ID=33017336

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29711A MA28822B1 (fr) 2004-08-11 2007-02-22 Benzamides substitues trifluoromethyle comme inhibiteurs de kinase

Country Status (17)

Country Link
US (2) US20080096883A1 (fr)
EP (1) EP1778640A1 (fr)
JP (1) JP2008509187A (fr)
KR (1) KR20070046851A (fr)
CN (2) CN101696188A (fr)
AU (1) AU2005270313A1 (fr)
BR (1) BRPI0514288A (fr)
CA (1) CA2575316A1 (fr)
EC (1) ECSP077235A (fr)
GB (1) GB0417905D0 (fr)
IL (1) IL181169A0 (fr)
MA (1) MA28822B1 (fr)
MX (1) MX2007001642A (fr)
NO (1) NO20071300L (fr)
RU (1) RU2007108861A (fr)
TN (1) TNSN07048A1 (fr)
WO (1) WO2006015859A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) † 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP1878727A4 (fr) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd Dérivés de 2-aminoquinazoline
BRPI0709749A2 (pt) * 2006-04-05 2011-07-26 Novartis Ag combinaÇÕes de agentes terapÊuticos para tratamento de cÂncer
MX2009000374A (es) * 2006-07-13 2009-01-27 Novartis Ag Uso de benzamidas substituidas con trifluorometilo en el tratamiento de trastornos neurologicos.
WO2008009078A2 (fr) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
WO2008030466A1 (fr) * 2006-09-05 2008-03-13 Amgen Inc. Composés de phtalazine, d'aza-phtalazine et de diaza-phtalazine et procédés d'utilisation
EP2117544A4 (fr) * 2006-12-19 2010-03-03 Univ Texas Biomarqueur permettant d'identifier la reactivation de la stat3 apres inhibition de src
JP5492565B2 (ja) * 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
CA2685674C (fr) * 2007-05-07 2012-07-17 Amgen Inc. Composes pyrazolo-pyridinone, leur procede de preparation et leur procede d'utilisation pharmaceutique
CA2685597C (fr) 2007-05-07 2012-10-02 Amgen Inc. Composes pyrazolo-pyridinone et pyrazolo-pyrazinone servant de modulateurs de p38, leur procede de preparation et leur procede d'utilisation pharmaceutique
US20100292292A1 (en) * 2007-09-13 2010-11-18 Link Medicine Corporation Treatment of Neurodegenerative Diseases Using Indatraline Analogs
US8367671B2 (en) * 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
US20110039845A1 (en) 2008-04-23 2011-02-17 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
WO2010025202A1 (fr) 2008-08-29 2010-03-04 Amgen Inc. Composés pyrido[3,2-d]pyridazine-2(1h)-one en tant que modulateurs de p38 et leurs procédés d'utilisation
ES2387474T3 (es) 2008-08-29 2012-09-24 Amgen, Inc Compuestos de piridazino-piridinona para el tratamiento de enfermedades mediadas por proteína cinasa
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
CN102573484B (zh) 2009-06-09 2015-07-01 加利福尼亚资本权益有限责任公司 苄基取代的三嗪衍生物及其治疗应用
CN102573480B (zh) 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
US9345699B2 (en) 2009-06-09 2016-05-24 Nantbioscience, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
EP2493460A4 (fr) * 2009-10-30 2013-04-24 Ariad Pharma Inc Procédés et compositions pour le traitement du cancer
CN102675289B (zh) * 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
WO2012148792A1 (fr) * 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Utilisation de composés hétérocycliques comme inhibiteurs de b-raf dans le traitement du cancer
ME02893B (fr) 2015-03-04 2018-04-20 Gilead Sciences Inc Composés 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du récepteur de type toll
EP3507288B1 (fr) 2016-09-02 2020-08-26 Gilead Sciences, Inc. Dérivés de 4,6-diamino-pyrido[3,2-d]pyrimidine en tant que modulateurs du recepteur de type toll
EP3507276B1 (fr) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Composés modulateurs du recepteur de type toll
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物
KR102463217B1 (ko) * 2020-07-13 2022-11-07 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111925331A (zh) * 2020-07-14 2020-11-13 上海毕得医药科技有限公司 一种6-溴酞嗪的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587829B1 (en) * 1997-07-31 2003-07-01 Schering Corporation Method and apparatus for improving patient compliance with prescriptions
US6523009B1 (en) * 1999-11-06 2003-02-18 Bobbi L. Wilkins Individualized patient electronic medical records system
US20030236682A1 (en) * 1999-11-08 2003-12-25 Heyer Charlette L. Method and system for managing a healthcare network
US6684276B2 (en) * 2001-03-28 2004-01-27 Thomas M. Walker Patient encounter electronic medical record system, method, and computer product
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
CN101039914A (zh) 2007-09-19
CN101696188A (zh) 2010-04-21
TNSN07048A1 (en) 2008-06-02
RU2007108861A (ru) 2008-09-20
US20080096883A1 (en) 2008-04-24
IL181169A0 (en) 2007-07-04
EP1778640A1 (fr) 2007-05-02
WO2006015859A1 (fr) 2006-02-16
MX2007001642A (es) 2007-04-10
BRPI0514288A (pt) 2008-06-10
JP2008509187A (ja) 2008-03-27
AU2005270313A1 (en) 2006-02-16
KR20070046851A (ko) 2007-05-03
ECSP077235A (es) 2007-03-29
CA2575316A1 (fr) 2006-02-16
NO20071300L (no) 2007-04-19
US20060035897A1 (en) 2006-02-16
GB0417905D0 (en) 2004-09-15

Similar Documents

Publication Publication Date Title
MA28822B1 (fr) Benzamides substitues trifluoromethyle comme inhibiteurs de kinase
MA28876B1 (fr) Amides bicycliques comme inhibiteurs de kinases
IL177007A0 (en) 2-(3-substituted-aryl) amino-4-thiazoles as tyrosine kinase inhibitors
IL181811A (en) Phenylaminopyrimidines are conserved in trifluoromethyl as inhibitors of @ - @ abl - @ bcr @@ kinase
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
DK1704145T3 (da) Selektive kinaseinhibitorer
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
IL179280A0 (en) Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
IL177278A0 (en) Pyrazolotriazines as kinase inhibitors
DE602005015215D1 (de) Orthosubstituierte aryl- oder heteroarylamidverbindungen
DK1713805T3 (da) Kinaseinhibitorer
ATE493403T1 (de) Kinaseinhibitoren
MA28698B1 (fr) Dicetopiperazines substituees utilisees comme antagonistes des oxytocines
ATE520664T1 (de) Tyrosinkinase-hemmer
ITMI20042239A1 (it) Additivi per fluoropolieterei
SE0400022D0 (sv) New compounds
DE602005008061D1 (de) Kinaseinhibitoren
SE0400254D0 (sv) New compounds
DK1737451T3 (da) Monocykliske heterocykler som kinase-inhibitorer
DE602005017159D1 (de) Oxysteroid-dehydrogenase-inhibitoren
DE602006019301D1 (de) Kinaseinhibitoren
UA9719S (uk) Стіл
UA9745S (uk) Стіл
UA9746S (uk) Стіл
UA9725S (uk) Стіл